Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved MabThera er større end risiciene ved behandling af non- Hodgkins lymfom og reumatoid arthritis.
The Committee for Medicinal Products for Human Use (CHMP) decided that MabThera’ s benefits are greater than its risks for the treatment of non-Hodgkin’ s lymphoma and rheumatoid arthritis.